SPI-1005 Treatment in Moderate COVID-19 Patients
Public ClinicalTrials.gov record NCT04484025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
Study identification
- NCT ID
- NCT04484025
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Interventions
- Ebselen Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2021
- Primary completion
- Dec 30, 2023
- Completion
- Dec 30, 2023
- Last update posted
- Oct 2, 2023
2021 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06510 | — |
| St. Luke's Cystic Fibrosis Center of Idaho | Boise | Idaho | 83702 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66160 | — |
| Washington University in St. Louis | St Louis | Missouri | 63130 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Wake Forest University | Winston-Salem | North Carolina | 27109 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04484025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04484025 live on ClinicalTrials.gov.